Over the past 12 years, it has become increasingly recognized that insulin resistance is central to the pathogenesis of the polycystic ovarian syndrome (PCOS). The use of insulin-sensitizing agents, such as Metformin, a biguanide insulin-lowering agent in ovulation induction for IVF, has been widely studied.
Reprinted with permission of IVF Worldwide
Newsletter – February 21, 2010
Website – www.IVF-Worldwide.comThe number of IVF units registered on the website has increased to 3085
The survey was compiled by Dr. Matan Yemini, Director of the Diamond Institute, New Jersey USA.
Over the past 12 years, it has become increasingly recognized that insulin resistance is central to the pathogenesis of the polycystic ovarian syndrome (PCOS). The use of insulin-sensitizing agents, such as Metformin, a biguanide insulin-lowering agent in ovulation induction for IVF, has been widely studied.
The current survey examines variations in attitudes and therapeutic approaches related to Metformin use as part of the IVF treatment protocol. As can be seen, variations exist, and to a large extent reflect lack of solid and evidenced-based data in this field.
Report from 101 centers worldwide performing 50,800 IVF cycles annually, of which 5,260 include Metformin, thus representing 10.4%
The report presented below is based on IVF cycles and not on centers.
It is interesting to note that 75% reported that the data available in the literature is insufficient to reach a decision concerning efficacy of the treatment.
The indications for treatment are not unanimous, as can see below.
Obesity with anovulation was the most common indication reported for treatment.
Only 25% reported that the indication for treatment with Metformin is also glucose intolerance and insulin resistance.
It is noteworthy that the majority who responded to the survey believe that Metformin may improve results in poor-responder patients.
Habitual abortion also serves as an indication for Metformin use.
Those who measure insulin consider high insulin as an indication for Metformin.
Glucose is measured by 66% of the reporting centers before starting Metformin.
Glucose insulin ration is measured by 38%, and the normal values according to the reporting centers vary from 4 to 7. Usually is it accepted that less than 4.5 is suggestive of insulin resistance.
The majority reported that they start Metformin between 1 and 3 months prior to initiating treatment.
Most of the reporting centers use a dose between 1500 and 2000 mg/day.
Perhaps the slow release is not as popular?
The majority do not follow up treatment with any specific blood test.
The majority continue treatment into the pregnancy period. It is interesting that 48% received treatment until the 12th gestational week and 12% continued treatment until delivery.
The majority reported that based on their experience; there is no correlation between the two.
Most of the reported centers believe that treatment with Metformin increases pregnancy rate.
And reduces rate of abortion.
No limit of treatment duration is definitely reported.
Comments received and printed (unedited version):
You may use the attached logo in your website in order to provide the link:
If you have any questions or comments please contact us at: contact@IVF-Worldwide.com
Prof. Zeev Shoham and Prof. Milton Leong
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More